

FEB 20 2001

Sheet 1 of 1

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07265-191001	Application No. 09/627,600
	Applicant Isaacs et al.		
	Filing Date July 28, 2000	Group Art Unit	

U.S. Patent Documents

Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
SWL	AA	5,905,089	05/18/1999	Hwang et al.	514	468	
I	AB	5,866,679	02/02/1999	DeFeo-Jones et al.	530	322	
I	AC	5,741,821	04/21/1998	Roufogalis et al.	514	734	
SWL	AD	5,599,686	02/04/1997	DeFeo-Jones et al.	435	23	

Foreign Patent Documents or Published Foreign Patent Applications


Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AE	WO 99/02175	01/21/1999	PCT				
	AF	WO 96/00503	01/11/1996	PCT				

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
SWL	AG	Treiman et al., "A tool coming of age: thapsigargin as an inhibitor of sarco-endoplasmic reticulum Ca^{2+} -ATPases", <i>TIPS</i> , April 1998, Vol. 19, pp 131-135.
	AH	Anderen et al., " Ca^{2+} -ATPase Inhibitory Activity Of a Locked Analogue of Thapsigargin", <i>Bioorganic & Medicinal Chemistry Letters</i> , Vol. 4, No. 5, pp 657-660, 1994.
	AI	Nielsen et al., "Structure-Activity Relationships of Analogues of Thapsigargin Modified at O-11 and O-12", <i>J. Med. Chem.</i> , 1995, Vol. 38, pp 272-276.
	AJ	Bourgeois et al., "Serpine-derived Peptide Substrates...Kallikreins hK1 and hK2", <i>The Journal of Biological Chemistry</i> , Vol. 272, No. 47, Issue of Nov. 21, pp. 29590-29595, 1997.
	AK	Denmeade et al., "Specific and Efficient Peptide...of Prostate-specific Antigen", <i>Cancer Research</i> , Vol. 57, pp. 4924-4930, Nov. 1, 1997.
	AL	Coombs et al., "Substrate specificity of prostate-specific antigen (PSA)", <i>Chemistry & Biology</i> , Vol. 5, No. 9, Sep. 1998, pp 475-488.
	AM	Brillard-Bourdet et al., "Substrate specificity...extended interaction site", <i>BBA</i> , Vol. 1246, No. 1, 5 Jan., 1995, pp. 47-52.
	AN	Devi, "Consensus sequence...peptide precursors...sites", <i>FEBS LETTERS</i> , Vol. 280, No. 2, 25 March 1991, pp 189-194.
SWL	AO	Nakayama et al., "Consensus Sequence for Precursor Processing at Mono-arginyl Sites", <i>The Journal of Biological Chemistry</i> , Vol. 267, No. 23, Issue of Aug. 15, pp. 16335-16340, 1992.

Examiner Signature <i>SWL</i>	Date Considered 7-15-04
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)

Sheet 1 of 1

Substitute Form PTO-1449 (Modified) Supplemental Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07265-191001	Application No. 09/627,600
	Applicant Isaacs et al.		
	Filing Date July 28, 2000	Group Art Unit 1653	

RECEIVED

JAN 18 2002
TECH CENTER 1600/2900

U.S. Patent Documents							
Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
<i>SWL</i>	AA	5,955,431	9/21/1999	Stevens et al.	514	17	
<i>SWL</i>	AB	5,618,790	4/8/1997	Kennedy et al.	514	12	
<i>SWL</i>	AC	5,603,933	2/18/1997	Dwyer, IV et al.	424	185.1	

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
<i>SWL</i>	AD	3-15886	01/24/1991	Japan				
<i>SWL</i>	AE	WO 99/40930	08/19/1999	PCT				
<i>SWL</i>	AF	WO 98/20135	05/14/1998	PCT				
<i>SWL</i>	AG	WO 97/28272	08/07/1997	PCT				

Examiner Signature <i>SWL</i>	Date Considered 9-15-04
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)

FORM PTO-1449

ATTY DOCKET NO.

SERIAL NO.

71699/57109

09/627,600

INFORMATION DISCLOSURE STATEMENT

APPLICANT(S): Denmeade, et al.

FILING DATE:
07/28/00ART UNIT:
1653

UNITED STATES PATENT DOCUMENTS

EXAM. INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FIL. DATE IF APPR

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRAN YES/NO

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

SWL	BA	Dube, "LA KALLICREINE HK2 PEUT-ELLE FAVORISER LA PROGRESSION DES TUMEURS CANCEREUSES DE LA PROSTATE", Science and Medicine, 14(1):111-113 (1998)
SWL	BB	Bougeois et al., Serpin-derived peptide substrates for investigating the substrate specificity of human tissue kallikrein hkl and hk2", Journal of Biological Chemistry, 272(47):29590-29595 (1997)
SWL	BC	Lovgren et al., "Enzymatic action of human glandular kallikrein 2 (hK2): Substrate specificity and regulation by Zn ²⁺ and extracellular protease inhibitors", European Journal of Biochemistry, 262(3):781-789 (1999)
SWL	BD	Mikolajczyk et al., "Human glandular kallikrein, hK2, shows arginine-restricted specificity and forms complexes with plasma protease inhibitors", Prostate, 34(1):44-50 (1998)
SWL	BE	Denmeade et al., "ENZYMATIC ACTIVATION OF PRODRUGS BY PROSTATE-SPECIFIC ANTIGEN: TARGETED THERAPY FOR METASTATIC PROSTATE CANCER", Cancer Journal from Scientific American, 4, Suppl. 1:S15-S21 (1998)
SWL	BF	Denmeade et al., "Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen", Cancer Research, 58:2537-2540 (1994)
SWL	BG	James et al., "BASIC AMINO ACIDS PREDOMINATE IN THE SEQUENTIAL AUTOANTIGENIC DETERMINANTS OF THE SMALL NUCLEAR 70K RIBONUCLEOPROTEIN", Scandinavian Journal of Immunology, 39(6):557-566 (1994)
SWL	BH	Pimenta et al., "Specificity of human tissue kallikrein towards substrates containing Phe-Phe pair of amino acids", Biochemical Journal, 339(2):473-479 (1999)

Examiner:

Date:

9-15-04